<DOC>
	<DOCNO>NCT00648336</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's mercaptopurine 50 mg tablet Gate 's Purinethol® 50 mg tablet follow single , oral 50 mg ( 1 x 50 mg ) dose administer fasting condition .</brief_summary>
	<brief_title>Fasting Study Mercaptopurine 50 mg Purinethol® Tablets 50 mg</brief_title>
	<detailed_description />
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>1 . Age : 18 year old . 2 . Sex : Male 3 . Volunteers sterile ( documentation require ) course study , study screen 3 month study exit , nonsterile male volunteer must use spermicidecontaining barrier method contraception prevent pregnancy sexual partner . This advice document informed consent form . 4 . Weight : At least 60 kg ( 132 lb . ) within 15 % Ideal Body Weight ( IBW ) , reference Table `` '' Desirable Weights Adults '' '' Metropolitan Life Insurance Company , 1999 ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 5 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , 12lead ECG , hepatitis B hepatitis C test , HIV test , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiate screen , phencyclidine , methadone ) perform within 14 day initial dose study medication . 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobacco product within 1 year start study . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamin herbal supplement within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . History drug and/or alcohol abuse within 1 year start study . 6 . A positive result drug urine drug screen . 3 . Medications : 1 . Use medication within 14 day prior initial dose study medication . 2 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 3 . Use allopurinol aminosalicylates ( e.g . olsalazine , mesalamine , sulfasalazine ) within 3 month start study . 4 . Diseases : 1 . History significant chronic disease and/or hepatitis . 2 . Acute illness time either prestudy medical evaluation dosing . 3 . A positive HIV , hepatitis B , hepatitis C test . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 2 . Abnormal clinically relevant ECG tracing . 3 . Abnormal liver function test ( i.e . ALT ( SGPT ) , AST ( SGOT ) , alkaline phosphatase , bilirubin ) . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity mercaptopurine relate product . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Consumption grapefruit grapefruit containing product within 7 day drug administration . 11 . Family history deficiency enzyme thiopurine methyltransferase .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>